Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
NCT ID: NCT02778919
Last Updated: 2019-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2016-05-09
2018-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
NCT01395940
A Clinical Study of KLH-2109 in Patients With Endometriosis
NCT07015268
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
NCT01629420
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
NCT01533532
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
NCT05440383
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KLH-2109, lowest dose
KLH-2109
Placebo
KLH-2109, low dose
KLH-2109
Placebo
KLH-2109, medium dose
KLH-2109
Placebo
KLH-2109, high dose
KLH-2109
Placebo
First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
Placebo
Leuprorelin acetate
Active reference
Leuprorelin acetate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KLH-2109
Placebo
Leuprorelin acetate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kissei Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Locations, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KLH1204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.